Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21723076 | 0.87 | NPSR1 (0.64) | ALDH1A1GAANPSR1MAPTTSHR | |
| SCHEMBL23542681 | 0.80 | TP53 (0.59) | ALDH1A1GAAL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL23919240 | 0.78 | KMT2A (0.51) | GAATSHRKMT2A | |
| SCHEMBL1396563 | 0.78 | PSIP1 (0.53) | ALDH1A1NPSR1MAPTTSHRPOLB | |
| SCHEMBL21724689 | 0.76 | L3MBTL1 (0.52) | ALDH1A1MAPTL3MBTL1SMN1; SMN2ALOX15 | |
| SCHEMBL1374250 | 0.76 | ALDH1A1 (0.47) | ALDH1A1GAAMAPTMEN1KMT2A | |
| SCHEMBL23732506 | 0.75 | GAA (0.55) | ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL31248447 | 0.75 | CA12 (0.44) | ALDH1A1L3MBTL1TSHRKMT2APOLB | |
| SCHEMBL30811026 | 0.75 | CA12 (0.44) | ALDH1A1GAAMEN1KMT2APOLB | |
| SCHEMBL30811038 | 0.75 | PLCG1 (0.48) | GAANPSR1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234207-B2 | Halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative and use thereof | CUREVERSE INCORPORATED (KR) | 2025-02-25 | — | — | US | disclosed |
| CN-112930345-B | Novel halo- (3- (benzenesulfonyl) prop-1-ene) pyridine derivatives and use thereof | 库尔维斯株式会社 | 2024-09-24 | — | — | CN | disclosed |
| US-20210317083-A1 | NOVEL HALO-(3-(PHENYLSULFONYL)PROP-1-ENYL)PYRIDINE DERIVATIVE AND USE THEREOF | CUREVERSE INCORPORATED (KR) | 2021-10-14 | — | — | US | disclosed |
| US-20210317083-A1 | NOVEL HALO-(3-(PHENYLSULFONYL)PROP-1-ENYL)PYRIDINE DERIVATIVE AND USE THEREOF | CUREVERSE INCORPORATED (KR) | 2021-10-14 | — | — | US | disclosed |
| EP-3838896-A1 | NOVEL HALO-(3-(PHENYLSULFONYL)PROP-1-ENYL)PYRIDINE DERIVATIVE AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2021-06-23 | — | — | EP | disclosed |
| CN-112930345-A | Novel halo- (3- (phenylsulfonyl) prop-1-ene) pyridine derivatives and uses thereof | 韩国科学技术研究院 | 2021-06-08 | — | — | CN | disclosed |
| WO-2020036474-A1 | NOVEL HALO-(3-(PHENYLSULFONYL)PROP-1-ENYL)PYRIDINE DERIVATIVE AND USE THEREOF | 한국과학기술연구원 | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317083-A1 | NOVEL HALO-(3-(PHENYLSULFONYL)PROP-1-ENYL)PYRIDINE DERIVATIVE AND USE THEREOF | KEAP1, NFE2L2, BACH1 | ALDH1A1 1002/4885GAA 2123/4885NPSR1 3057/4885 |
| US-12234207-B2 | Halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative and use thereof | KEAP1, NFE2L2, NQO1 | ALDH1A1 649/4885GAA 2114/4885NPSR1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.